tiprankstipranks
Travere Therapeutics (CH:17R)
:17R
Switzerland Market
17R
Travere Therapeutics
RESEARCH TOOLSreports

Travere Therapeutics (17R) Financial Statements

0 Followers

Travere Therapeutics Financial Overview

Travere Therapeutics's market cap is currently CHF4.98B. The company's EPS TTM is CHF-0.72; its P/E ratio is -146.82; Travere Therapeutics is scheduled to report earnings on August 4, 2026, and the estimated EPS forecast is CHF0.02. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue$ 490.73M$ 233.18M$ 145.24M$ 109.46M$ 131.84M
Gross Profit$ 480.39M$ 225.43M$ 133.79M$ 105.04M$ 128.02M
Operating Income$ -62.82M$ -323.83M$ -388.14M$ -319.81M$ -199.43M
EBITDA$ 22.22M$ -265.77M$ -326.25M$ -299.42M$ -184.46M
Net Income$ -25.55M$ -321.55M$ -111.40M$ -278.48M$ -180.09M
Balance Sheet
Cash & Short-Term Investments$ 322.80M$ 370.70M$ 566.85M$ 450.25M$ 552.88M
Total Assets$ 605.19M$ 594.13M$ 788.91M$ 672.59M$ 776.63M
Total Debt$ 328.73M$ 401.58M$ 404.78M$ 407.49M$ 261.99M
Net Debt$ 235.70M$ 343.05M$ 346.61M$ 345.80M$ 96.23M
Total Liabilities$ 490.36M$ 535.05M$ 588.10M$ 629.73M$ 474.52M
Stockholders' Equity$ 114.83M$ 59.08M$ 200.81M$ 42.85M$ 302.11M
Cash Flow
Free Cash Flow$ 37.78M$ -338.69M$ -321.61M$ -214.66M$ -38.94M
Operating Cash Flow$ 37.78M$ -237.47M$ -280.02M$ -186.29M$ -14.79M
Investing Cash Flow$ 27.89M$ 99.33M$ 55.78M$ -32.55M$ -137.62M
Financing Cash Flow$ -33.47M$ 139.42M$ 218.75M$ 117.57M$ 231.68M
Currency in USD

Travere Therapeutics Earnings and Revenue History

Income Statement >

Travere Therapeutics Debt to Assets

Balance Sheet >

Travere Therapeutics Cash Flow

Cash Flow >

Travere Therapeutics Forecast EPS vs Actual EPS

Earnings >